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Abstract
Objective: The goal was to elucidate predictors of decreased free water clearance (DFWC) in very low birth weight (VLBW)
infants. We hypothesized that DFWC and fluid retention are linked to the severity of pulmonary problems and prolonged
respiratory support, especially to nCPAP treatment.
Methods: The investigation was carried out at Tampere University Hospital between 2001 and 2006. The study population
comprised 74 VLBW infants born at 29.21 (24.57–34.14) weeks of gestation. Median birth weight was 1175 (575–1490)
grams. We measured plasma and urine osmolality and 24-hour urine volume to calculate free water clearance (FWC) for
each infant. If FWC was less than 30 ml/kg/day the infant was classified as having DFWC.
Results: There were 38 (51.4%) infants with DFWC in the study population. The median duration of the observed DFT period
was 14 (4–44) days. The gestational age at birth was lower for DFWC infants compared to infants with normal FWC (NFWC),
28.29 (24.57–32.86) vs. 30.00 (25.57–34.14) weeks (p=0.001). DFWC infants also needed longer ventilator treatment, 2 (0–23)
vs. 0.50 (0–23) days (p=0.046), nCPAP treatment 30 (0–100) vs. 3 (0–41) days (p,0.0001) and longer oxygen
supplementation 47 (0–163) vs. 22 (0–74) days (p=0.011) than NFWC infants. All values presented here are medians with
ranges.
Conclusions: DFWC appears to be frequently connected with exacerbation and prolongation of pulmonary problems in
VLBW infants. Cautious fluid administration seems to be indicated in VLBW infants with prolonged respiratory problems and
DFWC.
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Introduction
Infants with bronchopulmonary dysplasia (BPD) appear to
suffer transiently from decreased free water clearance (DFWC) on
certain occasions [1,2]. This is manifested by systemic and
pulmonary edema, oliguria, hyponatremia and hypertension,
often currently managed with diuretics [3]. Intervention by fluid
restriction has also been recommended [4].
Earlier studies on fluid balance have concentrated on fluid
management during the first days after the birth and have shown
that restriction of fluid intake decreases the mortality and
morbidity in preterm infants [5,6]. It is, however, not clear, which
infants might get benefit from fluid restriction, and how long it is
needed in such cases.
An inappropriate arginine vasopressin (AVP) hypersecretion has
emerged as one of the factors underlying the tendency to fluid
retention in BPD infants [1,2]. AVP is a neurophyseal peptide
hormone which among other functions regulates fluid balance. In
our two earlier studies we showed AVP hypersecretion to induce
transient fluid retention in response to prolonged or otherwise
stressful birth in healthy term infants [7,8]. This stress response
appears to be purposeful and is evidently physiological, unlike the
fluid retention with VLBW infants observed in our present study.
Continuous positive airway pressure (CPAP) treatment increases
AVP secretion, reduces the secretion of natriuretic peptides and
imposes fluid retention [9,10,11,12,13]. The secretion of these
fluid balance homeostasis-regulating hormones is mutually inter-
twined. AVP stimulates a release of natriuretic peptides which
subsequently reduce AVP secretion through a negative feed-back
loop [14]. Natriuretic peptides are cardiac hormones which
modulate extracellular fluid volume and blood pressure by
stimulating natriuresis, vasodilation and inhibition of AVP release
in response to pressure or volume overload [14,15,16]. Hence at
least partially an iatrogenic imbalance in this homeostatic system
with the consequent fluid retention may exacerbate pulmonary
problems and further prolong need for the respiratory support of
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recent study with an animal model lends support to these
hypotheses [18].
In our clinical practice we have noted a tendency to fluid
retention in VLBW infants, linked to prolongation of pulmonary
problems and especially BPD. During past decades this phenom-
enon has been unfortunately disregarded in neonatological
research and also in clinical work. Our aim here was to identify
predictors of DFWC in a population of VLBW infants. We
hypothesized that the fluid retention tendency is linked to
pulmonary problems and a prolonged need of respiratory support,
especially nasal CPAP (nCPAP) treatment. As DFWC can be
regarded as an indirect indicator of AVP activity, we chose this
more convenient means in evaluating fluid balance.
Methods
The present investigation was carried out at Tampere
University Hospital between the years 2001 and 2006. The Ethics
Committee of the Pirkanmaa Hospital District approved the study
protocol and informed written consent was obtained from the
parents participating.
Infants of birth weight less than 1500 g without any major
congenital malformations or grade IV intraventricular hemor-
rhage were enrolled. Infants were considered small for gestational
age (SGA) if they were in the lowest 10th percentile of birth weight
and appropriate for gestational age if they were above 10th
percentile for each gestational week stratified by infant gender
[19].
Starting from the calendar age of about one week, free water
clearance (FWC) and fluid input (total enteral and/or parenteral
24-hour fluid intake)/output (urine output) ratio were determined
and weight, need of oxygen (O2) supplementation, assisted
ventilation and corticosteroid use at that time-point were recorded.
Thereafter, the corresponding data were collected sequentially at
two weeks’ intervals until 36 weeks’ corrected gestational age or
until the end of O2 supplementation, or until FWC normalized.
Diuretics or indomethacine were not administered on the study
day. The 24-hour urine volume was determined by weighing
diapers. Urine osmolality (U-Osm) was determined from a single
bag urine sample as closely simultaneous as possible with the blood
sample for serum osmolality (S-Osm) determination. From these
data the FWC was calculated by the following formula:
Free Water Clearance~
Urine output
Weight
| 1{
Urine osmolality
Serum osmolality

If FWC was less than 30 ml/kg/day the infant was classified as
having DFWC [1]. This mode of assessment was considered
reliable in that daily parenteral fluids were administered as
continuous infusions and daily enteral feedings in evenly divided
volumes at three hour’s intervals.
Prophylactic surfactant was administered to all infants born at
gestational ages less than 28 weeks, and at gestational ages 28–30
weeks if the mother had not received antenatal glucocorticoids
and/or the infant needed delivery room intubation. Infants of
gestational ages 30 weeks or more received surfactant as rescue
therapy for RDS at the discretion of the attending neonatologist.
The diagnosis of BPD was established at the calendar age of 28
days or at a corrected gestational age of 36 weeks in infants
[20,21,22]. The severity of BPD was graded according to the need
for O2 [22]. An O2 saturation target between 88 and 94% was
used in the unit. All chest radiographs, obtained according to
clinical indications were assessed by a pediatric radiologist. BPD
findings were classified as hazy to opaque or bubbly chest images
[23].
Between 2001 and 2005 U-Osm and S-Osm were determined
using a Cryomatic 3C2 (Advanced Instruments inc., Massachu-
setts, USA) analyzer by a method based on freezing point
measurement. After October 2005 these analyses were made by a
Knauer A0300 (Knauer, Berlin, Germany) analyzer, likewise
based on freezing point measurement.
Statistics
It was assumed that an infant with pulmonary problems
involving a need for O2 supplementation, nCPAP or mechanical
ventilation would have 30% lower free water clearance (FWC)
than an infant without such problems at 28 days of age. Based on
this assumption a preliminary power analysis was made and an
appropriate statistical power of 80% and a statistical significance of
p,0.05 were estimated to be achieved with 40 infants per group.
All data were analyzed using SPSS Statistics Release 17.0.0 (SPSS
Inc., Chicago, IL, USA). Continuous data were analyzed using
Spearman’s rank correlation, Mann-Whitney U-test or Kruskal
Wallis test, and discrete data were analyzed by the Pearson chi-
squared test or Fisher’s exact test. Results are expressed as
occurrences (%) or median (range) values. Kaplan-Meier survival
curves were analyzed using the Log Rank Cox-Mantel test. The
first survival analysis addressed the cumulative occurrence of
normal FWC between nCPAP-treated infants and those who
managed without it. In the second survival analysis the cumulative
occurrence of supplemental O2 need was compared between
infants with normal and abnormal fluid tolerances. Factors
associated with the infants’ decreased FWC were analyzed by
backward-stepwise logistic regression, with p,0.05 and a 95%
confidence interval (CI) to indicate statistical significance.
Covariates included in the model were sex, gestational age at
birth, birth weight, surfactant treatment, BPD diagnosis and
durations of ventilator treatment, nCPAP treatment and supple-
mental O2.
Results
The study population comprised 74 very low birth weight
(VLBW) infants of median 29.2 (range 24.6–34.1) weeks’ gestation.
The median birth weight was 1175 (range 575–1490) grams.
DFWC was detected in 38 (51.4%) infants (Table 1). The
median corrected gestational age at first DFWC finding was 31.0
(27.4–36.3) weeks and the median calendar age at this point was
21 (range 6–48) days. In 19 of these, FWC was first normal and
changed to DFWC in further measurements. At the time of the
first DFWC 25 (65.8%) of the infants received nCPAP treatment,
5 (13.2%) needed supplemental O2 and 8 did not need any of
these. None of the DFWC infants received mechanical ventilation
at this point.
FWC normalized in 25 (65.8%) of the DFWC infants. The
remaining 13 were transferred to their regional hospitals, or their
clinical condition otherwise improved and further FWC measure-
ments were not undertaken. The median duration of the observed
DFWC period was 14 (range 4–44) days. At the end of this period
the median corrected gestational age was 34.1 (range 28.4–38.3)
weeks and the median calendar age 40 (range 14–69) days. At this
point 12 (48.0%) infants still needed nCPAP treatment and three
(12.0%) supplemental O2.
In survival analysis we also observed a significant difference
(p=0.013) in DFWC occurrence between nCPAP-treated infants
and those who managed without it [Figure 1]. The need for
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in NFWC infants (p=0.004) [Figure 2].
Eighteen infants were treated with budesonide inhalations when
the first decreased FWC was determined. None of these infants
received systemic glucocorticoid treatment at this point. The
budesonide treatment was not associated with the duration of
DFWC nor with the need for respiratory support at the end of the
DFWC period.
In backward logistic regression analysis only the duration of
nCPAP treatment [p=0.001; odds ratio 1.059; 95% CI, 1.024–
1.095] predicted DFWC statistically significantly.
To establish occasion-related variables associated with low
FWC in DFWC infants we analyzed the fluid balance measure-
ments closest to 21 day’s postnatal age (Table 2). This time-point
(D21) was selected according to the median age at detection of
DFWC. At D21 there were 27 (36.5%) infants with DFWC
Table 1. Characteristics of 74 study infants.
DFWC NFWC p
Number of infants, n (%) 38 (51.4) 36 (48.6)
FWC measurements, Md (Range) 4 (1–6) 2 (1–6) ,0.001
Boys, n (%) 24 (63.2) 22 (61.1) 1.000
Gestational age at birth (wk), Md (Range) 28.3 (24.6–32.9) 30.0 (25.6–34.1) 0.001
Birth weight (g), Md (Range) 1050 (625–1490) 1280 (575–1490) 0.007
SGA, n (%) 6 (15.8) 12 (33.3) 0.106
Prenatal glucocorticoid, n (%) 34 (89.5) 31 (86.1) 0.618
Surfactant treatment, n (%) 29 (76.3) 18 (50.0) 0.029
BPD, n (%) 25 (65.8) 11 (32.4) 0.009
Moderate or severe BPD, n (%) 16 (42.1) 7 (19.4) 0.047
Assisted ventilation (days), Md (Range) 2 (0–23) 0.5 (0–23) 0.046
nCPAP (days), Md (Range) 30 (0–100) 3 (0–41) ,0.001
O2 supplementation (days), Md (Range) 47 (0–163) 22 (0–74) 0.011
Hospitalization (days), Md (Range) 72 (26–15) 53 (22–262) ,0.001
Diuretic treatment, n (%) 8 (21.1) 5 (13.9) 0.545
Indomethacin treatment, n (%) 0 (0) 2 (5.6) 0.233
Died, n (%) 1 1(2.6) 1 (2.8) 1.000
Results are expressed as occurrences (%) or median (range) values with statistical significance (p)*.
*Differences between DFWC and NFWC were tested by Mann-Whitney test or by Pearson chi-square or Fisher’s exact test.
doi:10.1371/journal.pone.0016995.t001
Figure 1. The cumulative occurrence of normal FWC between nCPAP-treated infants and infants who managed without it.
doi:10.1371/journal.pone.0016995.g001
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9 (12.2%) developed DFWC later, as shown in Figure 1. Since
these 11 infants did not evince DFWC at D21 they were excluded
from this analysis. Corresponding measurements at D21
(NFWC21) in study infants with normal FWC were analyzed as
control data.
A significant negative correlation was observed between FWC
and the duration of nCPAP treatment before D21 (r=20.335,
p=0.007). BPD findings in chest X-ray images obtained closest to
D21 were associated with decreased FWC 12.3 (2213.8–92.9) vs.
56.2 (29.0–89.9) ml/kg/day (p,0.001). Since all chest X-ray
images were taken on clinical indications, we here reviewed the
Figure 2. The cumulative occurrence of supplemental oxygen compared between infants with normal and abnormal fluid
tolerances.
doi:10.1371/journal.pone.0016995.g002
Table 2. Fluid balance data at postnatal age of 21 days in infants with abnormal and normal free water clearance.
DFWC21 (n=27) NFWC21 (n=36) p
Boys, n (%) 18 (66.7) 22 (61.1) 0.793
Gestational age at birth (wk), Md (Range) 27.7 (24.6–32.9) 30.0 (25.6–34.1) 0.001
Birth weight (g), Md (Range) 1005 (625–1490) 1280 (575–1490) 0.003
SGA, n (%) 4 (14.8) 12 (33.3) 0.095
Weight at D21 (g), Md (Range) 1141 (705–2045) 1565 (792–2120) 0.005
Free water clearance (g/kg/d), Md (Range) 24.9 (2213.8–28.5) 57.1 (34.3–92.9) ,0.001
Serum osmolality (mOsm/L), Md (Range) 272 (256–296) 276 (260–295) 0.140
Urine osmolality (mOsm/L), Md (Range) 280 (189–701) 141.5 (75–185) ,0.001
Fluid intake (ml/kg/d), Md (Range) 171.8 (117.1–195.9) 176.6 (134.1–229.1) 0.013
Urine volume (ml/kg/d) 99.0 (39.2–241.7) 120.0 (60.9–177.9) 0.004
Intake/Output ratio, Md (Range) 1.61 (0.62–2.65) 1.47 (0.94–3.10) 0.092
Ongoing nCPAP treatment, n (%) 17 (63.0) 12 (33.3) 0.024
Before D21 duration, Md (Range)
nCPAP treatment 12 0–22) 3 (0–21) 0.025
Assisted ventilation 20 (0–28) 7 (0–24) 0.011
Results are expressed as occurrences (%) or median (range) values with statistical significance (p)*.
*Differences between DFWC21 and NFWC21 were tested by Mann-Whitney test or by Pearson chi-square or Fisher’s exact test.
doi:10.1371/journal.pone.0016995.t002
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17) days.
Discussion
Earlier clinical studies have concentrated mainly on fluid
management of premature infants’ early days or first week [5,6].
In our work we focused on long-term fluid management and used
FWC to evaluate and monitor fluid balance and retention.
The results of this study suggest that low FWC is associated with
pulmonary problems in VLBW infants. As these problems
decrease free water clearance also will eventually normalize. This
coincides with our clinical experiences and supports earlier
hypotheses regarding poor tolerance to fluids in such infants.
Nonetheless, the precise etiology and the underlying pathophys-
iology of decreased fluid tolerance in this patient group remain
unclear.
There was a statistically significant difference between the
median fluid intake at D21 between DFWC21 and NFWC21
infants. The difference between the two figures was notably small,
about five ml/kg/day, and therefore not clinically significant. The
aim was not to blind the clinicians for the FWC results, because
infants with DFWC get benefit from restricted fluid administra-
tion. Bias due to this is, however, very unlikely, because same
guidelines for weaning from respiratory support and oxygen
supplementation were followed in the treatment of all infants in
the unit. If any bias would exist, it would not change the main
results, because fluid restriction would more probably alleviate
than increase the need of respiratory support and oxygen
supplementation. The urine volumes were lower and U-Osm
higher in the DFWC group compared to NFWC cases, but
conversely, S-Osm tended to be lower in the infants with DFWC
than in NFWC cases. The differences cannot thus be explained by
dehydration in the patients with DFWC.
Gestational age at birth and birth weight were lower among
DFWC infants. The greater immaturity of DFWC infants
obviously predicted higher frequencies of surfactant treatment
and BPD in this group, and DFWC infants accordingly needed
longer periods of ventilator treatment, supplemental O2 and
hospitalization than NFWC infants. Immaturity is nonetheless
unlikely to be the sole predictor of DFWC problems, since there
was wide variance in corrected gestational age at the first
decreased FWC. This reasoning is further substantiated by the
result of the logistic regression analysis and the fact that in half of
the DFWC cases the FWC was normal in the first measurement.
We observed a marked association between the occurrence of
DFWC and the duration of nCPAP treatment, this again lending
support to earlier findings [9,10,11,12,13,14,15]. As shown in
Figure 1, nCPAP-treated infants developed DFWC more
frequently than infants who managed without it.
Mechanical ventilation and positive airway pressure induce fluid
retention through multiple intertwined mechanisms. These include
positive end-expiratory pressure, raising intrathoracic and hence
inferior vena cava pressure, and both in turn stimulate AVP
secretion [9,10,15]. Secondly, positive airway pressure has also
been shown to reduce ANP secretion by reducing atrial distension
[11,12]. Finally, mechanical ventilation and CPAP treatment also
cause fluid retention without any changes in AVP or renin activity,
probably in consequence of diminished cardiac output [13].
Previously Hazinski and associates measured AVP levels in infants
with chronic BPD and DFWC [1]. Direct measurement of AVP
activity is, however, poorly suitable for clinical work in that it is
expensive and relatively time-consuming, as we have experienced
with AVP radioimmunoassays [7].
Imbalance in fluid homeostasis in DFWC infants seems to be
caused by inappropriate AVP hypersecretion due various non-
osmotic stimuli from stress, hypoxia and also directly from
respiratory support, especially from positive airway pressure as
previously described [1,2,9,10,11,12,13,15,16,20,24]. Our present
results lend strong support to these previous findings. Also the
analysis at D21 would advocate such an interpretation to an even
greater extent. The long duration of nCPAP treatment and
respiratory support were strong predictors of DFWC. Also the
majority of DFWC infants were treated with nCPAP at the time of
the first decreased FWC measurement.
DFWC infants required O2 supplementation longer than
NFWC infants [Figure 2]. As we hypothesized, fluid retention
causes pulmonary edema and further impairs DFWC infants’
oxygenation, and will prolong and aggravate BPD. Also, as
Hazinski suggested based on earlier studies of BPD and status
asthmaticus [25–27], reduced pulmonary functional residual
capacity and increased alveolar dead space lead to increased intra
thoracic pressure and decreased venous return to the left atrium
[1]. This increases AVP secretion and causes poor tolerance to
fluids in BPD patients even without nCPAP treatment [1]. The
same phenomenon was noted in chest radiographs taken at D21.
These revealed a significant association between low FWC and
abnormal findings related to BPD. DFWC seems thus to be a
vicious cycle which needs to be recognized. In light of this,
excessive fluid administration needs to be avoided in VLBW
infants with prolonged pulmonary problems and in such cases fluid
restriction might be more beneficial mode of treatment than
diuretics. In this way, the side-effects of diuretics can also be
avoided. During the fluid restriction period it is paramount to
ascertain that these infants attain adequate caloric intake in order
to thrive.
Conclusions
The present findings suggest that DFWC is markedly associated
with exacerbation and prolongation of pulmonary problems and
the need for nCPAP treatment in VLBW infants. As also shown in
earlier studies, the hypersecretion of AVP stimulated by various
circulatory and pulmonary mechanical factors would appear to
induce fluid retention. In establishing, whether the infant’s fluid
intake needs to be cautious, fluid tolerance can be assessed by
determining FWC.
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